(Q43841175)

27 November 2017

title

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles (English)

1 reference

27 November 2017

1 reference

4

1 reference

27 November 2017

Paola Di Gion

1

1 reference

27 November 2017

Friederike Kanefendt

2

1 reference

27 November 2017

Andreas Lindauer

3

1 reference

27 November 2017

Oxana Doroshyenko

5

1 reference

27 November 2017

Uwe Fuhr

6

1 reference

27 November 2017

Jürgen Wolf

7

1 reference

27 November 2017

Ulrich Jaehde

8

1 reference

27 November 2017

publication date

1 September 2011

1 reference

Clinical Pharmacokinetics

27 November 2017

published in

1 reference

27 November 2017

volume

50

1 reference

27 November 2017

issue

9

1 reference

27 November 2017

page(s)

551-603

1 reference

The protein tyrosine kinase family of the human genome

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Tyrosine kinase inhibitors: the first decade

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Imatinib: the first 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Metabolism and disposition of imatinib mesylate in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Kinase inhibitors in cancer therapy: a look ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Issues and progress with protein kinase inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Discovery of a novel Raf kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

The vascular endothelial growth factor family and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

BAY 43-9006 inhibition of oncogenic RET mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Biology of gastrointestinal stromal tumors: KIT mutations and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effect of antacid on imatinib absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effect of St John's wort on imatinib mesylate pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Imatinib for hepatocellular cancer--focus on pharmacokinetic/pharmacodynamic modelling and liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacogenomic importance of ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Metabolism and disposition of dasatinib after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Sorafenib for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Imatinib use during pregnancy and breast feeding: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Population pharmacokinetic analysis of sorafenib in patients with solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Alpha-1-acid glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Human alpha-1-glycoprotein and its interactions with drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Targeted drugs in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetics of sunitinib in an obese patient with a GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Inhibition of imatinib transport by uremic toxins during renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Imatinib for patients with liver or kidney dysfunction: no need to modify the dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetics of sunitinib in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effect of hemodialysis on hepatic cytochrome P450 functional expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effect of a proton pump inhibitor on the pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Marginal increase of sunitinib exposure by grapefruit juice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Interaction of imatinib with human organic ion carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Environmental and genetic factors affecting transport of imatinib by OATP1A2

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Dasatinib: is it all in the dose?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

RAF/RAS oncogenes and mismatch-repair status

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593320-000000000-00000

Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.

21 January 2018

1 reference

12 December 2020

Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL

1 reference

12 December 2020

Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study

1 reference

12 December 2020

Drug binding to human alpha-1-acid glycoprotein in health and disease

1 reference

12 December 2020

Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors

1 reference

12 December 2020

1 reference

12 December 2020

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs

1 reference

12 December 2020

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma

1 reference

12 December 2020

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors

1 reference

12 December 2020

Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors

1 reference

12 December 2020

Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome

1 reference

12 December 2020

Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients

1 reference

12 December 2020

Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

1 reference

12 December 2020

Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy

1 reference

12 December 2020

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

1 reference

12 December 2020

Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib

1 reference

12 December 2020

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

1 reference

12 December 2020

Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk

1 reference

12 December 2020

A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine

1 reference

12 December 2020

Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma

1 reference

12 December 2020

Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma

1 reference

12 December 2020

Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype

1 reference

12 December 2020

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors

1 reference

12 December 2020

Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.

1 reference

12 December 2020

Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors

1 reference

12 December 2020

Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group.

1 reference

12 December 2020

Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis.

1 reference

12 December 2020

Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer

1 reference

12 December 2020

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

12 December 2020

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib

1 reference

12 December 2020

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results

1 reference

12 December 2020

Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.

1 reference

12 December 2020

Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial

1 reference

12 December 2020

The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1

1 reference

12 December 2020

A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay

1 reference

12 December 2020

Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2

1 reference

12 December 2020

The role of cytochromes P-450 in cyclosporine metabolism

1 reference

12 December 2020

Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib

1 reference

12 December 2020

Vascular endothelial growth factor as a therapeutic target in cancer

1 reference

12 December 2020

Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors

1 reference

12 December 2020

Pazopanib for the treatment of patients with advanced renal cell carcinoma

1 reference

12 December 2020

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study

1 reference

12 December 2020

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Decreased in vivo metabolism of drugs in chronic renal failure

1 reference

12 December 2020

Is rectal administration an alternative route for imatinib?

1 reference

12 December 2020

Metoclopramide treatment in DBA patients: no complete response in a French prospective study

1 reference

12 December 2020

10.2165/11593320-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 November 2017

1007132094

0 references

1 reference